139 related articles for article (PubMed ID: 17509041)
1. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.
Tayab ZR; Fardon TC; Lee DK; Haggart K; McFarlane LC; Lipworth BJ; Hochhaus G
Br J Clin Pharmacol; 2007 Nov; 64(5):698-705. PubMed ID: 17509041
[TBL] [Abstract][Full Text] [Related]
2. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.
Fardon TC; Lee DK; Haggart K; McFarlane LC; Lipworth BJ
Am J Respir Crit Care Med; 2004 Nov; 170(9):960-6. PubMed ID: 15184207
[TBL] [Abstract][Full Text] [Related]
3. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN
Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
[TBL] [Abstract][Full Text] [Related]
4. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
Daley-Yates PT; Deans A; Mehta R; Sousa AR
Pulm Pharmacol Ther; 2022 Dec; 77():102171. PubMed ID: 36243386
[TBL] [Abstract][Full Text] [Related]
5. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.
Affrime MB; Kosoglou T; Thonoor CM; Flannery BE; Herron JM
Chest; 2000 Dec; 118(6):1538-46. PubMed ID: 11115437
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays.
Daley-Yates PT; Kunka RL; Yin Y; Andrews SM; Callejas S; Ng C
Eur J Clin Pharmacol; 2004 Jun; 60(4):265-8. PubMed ID: 15114430
[TBL] [Abstract][Full Text] [Related]
7. Treatment with inhaled mometasone furoate reduces short-acting β(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients.
Navaratnam P; Friedman HS; Urdaneta E
Value Health; 2011; 14(2):339-46. PubMed ID: 21402302
[TBL] [Abstract][Full Text] [Related]
8. Systemic bioavailability of inhaled corticosteroids: appropriate and comparable methodology.
Affrime MB; Banfield C; Nolop K
Eur Respir J; 2001 Jul; 18(1):246. PubMed ID: 11510799
[No Abstract] [Full Text] [Related]
9. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.
Skoner DP; Meltzer EO; Milgrom H; Stryszak P; Teper A; Staudinger H
J Asthma; 2011 Oct; 48(8):848-59. PubMed ID: 21854342
[TBL] [Abstract][Full Text] [Related]
10. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate.
Crim C; Pierre LN; Daley-Yates PT
Clin Ther; 2001 Sep; 23(9):1339-54. PubMed ID: 11589253
[TBL] [Abstract][Full Text] [Related]
11. Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology.
Derendorf H; Daley-Yates PT; Pierre LN; Efthimiou J
Eur Respir J; 2001 Jan; 17(1):157-8. PubMed ID: 11307748
[No Abstract] [Full Text] [Related]
12. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial.
Harnest U; Price D; Howes T; Sussman G
J Asthma; 2008 Apr; 45(3):215-20. PubMed ID: 18415829
[TBL] [Abstract][Full Text] [Related]
13. Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma.
Skoner DP; Gentile DA; Angelini B
Allergy Asthma Proc; 2010; 31(1):10-9. PubMed ID: 20167141
[TBL] [Abstract][Full Text] [Related]
14. The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers.
Mackie AE; Bye A
Clin Pharmacokinet; 2000; 39 Suppl 1():47-54. PubMed ID: 11140433
[TBL] [Abstract][Full Text] [Related]
15. The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease.
Lee DK; Lipworth BJ
Br J Clin Pharmacol; 2004 Apr; 57(4):388-92. PubMed ID: 15025735
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease.
Singh SD; Whale C; Houghton N; Daley-Yates P; Kirby SM; Woodcock AA
Br J Clin Pharmacol; 2003 Apr; 55(4):375-81. PubMed ID: 12680886
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate.
Wardlaw A; Larivee P; Eller J; Cockcroft DW; Ghaly L; Harris AG
Ann Allergy Asthma Immunol; 2004 Jul; 93(1):49-55. PubMed ID: 15281471
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers.
Affrime MB; Cuss F; Padhi D; Wirth M; Pai S; Clement RP; Lim J; Kantesaria B; Alton K; Cayen MN
J Clin Pharmacol; 2000 Nov; 40(11):1227-36. PubMed ID: 11075308
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma.
Daley-Yates PT; Tournant J; Kunka RL
Clin Pharmacokinet; 2000; 39 Suppl 1():39-45. PubMed ID: 11140432
[TBL] [Abstract][Full Text] [Related]
20. Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma.
Friedman HS; Navaratnam P; McLaughlin J
J Asthma; 2010 Nov; 47(9):994-1000. PubMed ID: 20831468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
